383 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Editas Inks Deal for Gene Editing Neurological Disease Drugs http://www.zacks.com/stock/news/567847/editas-inks-deal-for-gene-editing-neurological-disease-drugs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-567847 Oct 16, 2019 - Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up http://www.zacks.com/stock/news/563815/aclaris-divests-rhofade-to-epi-health-for-%2455m-shares-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563815 Oct 14, 2019 - Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements http://www.zacks.com/stock/news/557772/wet-amd-space-in-focus-new-drug-approvals-key-advancements?cid=CS-ZC-FT-analyst_blog|industry_focus-557772 Oct 10, 2019 - The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539102 Sep 27, 2019 - IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet http://www.zacks.com/research-daily/531879/top-analyst-reports-for-bristol-myers-squibb-lockheed-martin-alphabet?cid=CS-ZC-FT-research_daily-531879 Sep 23, 2019 - Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet
Coalition urges FTC block to ABBV-AGN deal https://seekingalpha.com/news/3499276-coalition-urges-ftc-block-abbv-agn-deal?source=feed_news_all Sep 13, 2019 - Consumer groups and unions want the FTC to block AbbVie's (ABBV +0.4%) $63B acquisition of Allergan (AGN), according to a STAT report.The coalition says the increasingly concentrated nature of the hea
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment http://www.zacks.com/stock/news/516990/ardelyx-gets-fda-approval-for-ibsrela-as-ibs-c-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-516990 Sep 13, 2019 - Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others http://www.zacks.com/stock/news/516828/pharma-stock-roundup-pipeline-regulatory-updates-from-gsk-pfe-others?cid=CS-ZC-FT-analyst_blog|stock_roundup-516828 Sep 13, 2019 - Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe http://www.zacks.com/stock/news/512573/allergans-filings-for-abicipar-pegol-accepted-in-us-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-512573 Sep 11, 2019 - The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
ETFs Poised to Benefit from Gene Editing Revolution http://www.zacks.com/stock/news/505549/etfs-poised-to-benefit-from-gene-editing-revolution?cid=CS-ZC-FT-etf_news_and_commentary-505549 Sep 06, 2019 - Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

Pages: 123456789...39

<<<Page 4>